Zero malaria deaths are possible—but only if we harness the full power of innovation, partnership, and evidence-based action

Image Credit: IVCC/ LITE/ Derric Nimmo

Zero malaria deaths are possible—but only if we harness the full power of innovation, partnership, and evidence-based action.

IVCC CEO Justin McBeath, and IVCC Trustee Keziah Malm, in her role as Program Manager for Ghana’s National Malaria Elimination Program, join Medicines for Malaria Venture and PATH‘s Center for Vaccine Innovation and Access in this compelling opinion piece on achieving zero malaria deaths.

New insecticides are critical for combating resistance in mosquito populations and ensuring the continued effectiveness of widely used interventions such as insecticide-treated bed nets and indoor residual spraying. Vaccines RTS,S and R21 represent a breakthrough in reducing malaria morbidity and mortality, offering protection for children in areas with high and moderate transmission of Plasmodium falciparum, the deadliest form of the malaria parasite. Preventive interventions, such as seasonal malaria chemoprevention and intermittent preventive treatment in pregnancy, among others, protect the two populations most at risk: children and pregnant women.

While each of these tools has significant benefits on its own, their combined use creates a multilayered defense against malaria that is far more powerful than any single intervention. All three are needed to prevent malaria and reduce deaths in different populations and contexts.

Read their insights on how collaboration can transform global health, published in Devex, by following this link: https://ow.ly/KkZ350UBHzE